Fusion Antibodies (LON:FAB) Stock Price Up 3.9% – Still a Buy?

Fusion Antibodies plc (LON:FAB) shares rose 3.9% during mid-day trading on Tuesday . The company traded as high as GBX 6.50 ($0.09) and last traded at GBX 6.39 ($0.08). Approximately 2,294,034 shares were traded during trading, an increase of 73% from the average daily volume of 1,327,368 shares. The stock had previously closed at GBX 6.15 ($0.08).

Fusion Antibodies Price Performance

The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87. The company has a market capitalization of £5.95 million, a price-to-earnings ratio of -1.42 and a beta of 0.49. The company has a 50-day moving average price of GBX 7.58 and a 200-day moving average price of GBX 6.29.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.